Capital Wealth Planning LLC Sells 472,530 Shares of Amgen Inc. $AMGN

Capital Wealth Planning LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 36.4% in the third quarter, HoldingsChannel.com reports. The firm owned 825,780 shares of the medical research company’s stock after selling 472,530 shares during the quarter. Amgen comprises 1.6% of Capital Wealth Planning LLC’s investment portfolio, making the stock its 23rd largest position. Capital Wealth Planning LLC’s holdings in Amgen were worth $233,035,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Sequoia Financial Advisors LLC raised its stake in shares of Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after buying an additional 3,619 shares during the last quarter. Davis Capital Management bought a new position in Amgen in the third quarter valued at approximately $1,841,000. D.A. Davidson & CO. grew its holdings in Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after acquiring an additional 6,222 shares during the period. Global Wealth Management Investment Advisory Inc. grew its holdings in Amgen by 56.2% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after acquiring an additional 4,699 shares during the period. Finally, Jones Financial Companies Lllp raised its position in shares of Amgen by 18.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after acquiring an additional 6,115 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer?term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Amgen Price Performance

AMGN opened at $366.21 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a fifty day simple moving average of $357.73 and a 200 day simple moving average of $325.17. The stock has a market cap of $197.41 billion, a P/E ratio of 25.74, a P/E/G ratio of 3.65 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period in the previous year, the company posted $5.31 earnings per share. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent research reports. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. UBS Group increased their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Deutsche Bank Aktiengesellschaft raised their target price on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $354.00.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.